Subscribe

ASH 2014 - Castleman's Disease

Ibrutinib, a small-molecule inhibitor of BTK, has shown significant activity in several B-cell malignancies...
Single-agent ibrutinib has been approved by the FDA for patients with MCL who received at least 1 previous therapy based on a phase 2 clinical trial in which ibrutinib elicited a response rate of 68%...
Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphoma, accounting for approximately 30% of newly diagnosed cases in the United States...
Ibrutinib was shown in an international, multicenter, open-label, phase 2 trial to provide durable responses and to have a favorable safety profile in patients with relapsed or refractory MCL...
Despite recent advances, mantle-cell lymphoma (MCL) remains difficult to treat, with frequent chemoresistance in the relapsed or refractory setting...
Dysregulated production of hepcidin is implicated in anemia of inflammation, and IL-6 is a major inducer of hepcidin production...
MCD describes a heterogeneous group of poorly understood diseases involving proinflammatory hypercytokinemia that ultimately results in systemic inflammatory symptoms, generalized lymphadenopathy, multiple organ system dysfunction, and even death...
Siltuximab, a monoclonal antibody against IL-6, was recently approved in the United States and in Europe for the treatment of adults with MCD who are HIV-negative and HHV-8–negative...
Multicentric Castleman’s Disease (MCD) is a rare, highly symptomatic, systemic lymphoproliferative disorder driven by dysregulated interleukin (IL)-6 signaling...
Immunochemotherapy has become the standard of care for patients with mantel-cell lymphoma (MCL)...
Page 1 of 2
Results 1 - 10 of 19
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology